A $200 million guidance cut erased $12 billion of market value. The gap between those numbers is what a growth premium costs when growth is questioned.
Wandering tumour cells go quiet, switch off the distress signals that would summon immune cells, and wait. Disrupt the silence and the immune system finds them again.
Compounding law lets a pharmacist tailor a medicine for one patient. Marketing an untested formulation to clinics is a different activity wearing the same name.
$785 million for the right to decide later. The option structure is what companies do when a platform is promising and entirely preclinical.
Synlogic shareholders keep 2.3%. What is being bought is the listing, and the $278 million arriving alongside it.
The high dose beat an opioid combination on pain score and left 30 percentage points more patients never needing opioid rescue at all.
Two endpoints, face and body, measured separately — because in vitiligo where the pigment returns matters as much as how much.
T-cell engagers were built to kill cancer cells. Pointing them at a patient’s own misbehaving immune cells is the same weapon aimed inward.
Structure-based design assumes the target holds still. For a protein that never does, a single crystal structure is not simplification — it is fiction.
In the 106-patient HOPE-3 trial, boys and young men on deramiocel lost arm and elbow function markedly slower than those on placebo, ahead of an August FDA decision.
Not silencing the gene — changing how it is read, so the cell skips the section that produces the toxic fragments.
The acquisition brings 100,000 pediatric text messages. The data is the asset, and children are where AI accuracy claims face the hardest scrutiny.